Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

121. Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Drug-induced systemic lupus erythematosus associated with etanercept therapy. Specific antagonists of tumour necrosis factor (TNF)-alpha have rapidly gained popularity for the treatment of rheumatoid arthritis. The monoclonal antibody against TNF-alpha, infliximab, has been associated with induction of systemic lupus erythematosus (SLE); however, there have been no published reports of drug-induced SLE associated with the soluble TNF-alpha receptor etanercept. We describe four female patients (...) who developed signs and symptoms of SLE during treatment with etanercept; in two SLE was unambiguous. On diagnosis of SLE, etanercept was discontinued and the SLE-related symptoms promptly resolved. Etanercept should be considered in the list of agents associated with drug-induced SLE.

Lancet2002

122. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Jobanputra P, Barton P, Bryan S, Burls A, Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jobanputra P, Barton P, Bryan S, Burls A,. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(21): 1-110 Authors' objectives This report reviews the evidence for the clinical effectiveness and cost-effectiveness of etanercept

Health Technology Assessment (HTA) Database.2002

123. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept Cummins C, Connock M, Fry-Smith A, Burls A Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technology Assessment 2002; 6(17): 1-43 Authors' objectives This report aims: - To provide a background review on juvenile idiopathic arthritis (JIA), including epidemiology, current

Health Technology Assessment (HTA) Database.2002

124. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis

Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 36. 2002 Authors' objectives To provide guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Authors' conclusions Guidance 1.1 Etanercept and infliximab (infliximab only in combination with methotrexate) are recommended as options

Health Technology Assessment (HTA) Database.2002

125. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis

Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute (...) for Clinical Excellence. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 35. 2002 Authors' objectives To provide guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Authors' conclusions Guidance 1.1 Etanercept is recommended for children aged 4 to 17 years with active polyarticular-course juvenile idiopathic arthritis whose condition has

Health Technology Assessment (HTA) Database.2002

126. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept Cummins C, Connock M, Fry-Smith A, Burls A Authors' objectives To determine the benefits and hazards (...) of etanercept in juvenile idiopathic arthritis (JIA) compared with currently available treatments. Searching MEDLINE, EMBASE, the Science Citation Index and the Cochrane Library were searched from 1966 to the end of 2000. The MeSH terms used were 'arthritis, juvenile rheumatoid' and the keywords were 'juvenile idiopathic arthritis', 'juvenile rheumatoid arthritis', 'juvenile chronic arthritis', 'TNF', 'TNF receptors', 'anti-TNF', 'quality of life', 'etanercept' and 'infliximab'. Abstracts from relevant

DARE.2002

127. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Jobanputra P, Barton P, Bryan S, Burls A Authors' objectives The main objective was to assess (...) the clinical benefits and hazards of using etanercept and infliximab in rheumatoid arthritis. Searching MEDLINE (from 1996 to 2001), EMBASE (from 1998 to 2001), the Science Citation Index, the Cochrane Library and the National Research Register were searched; the search terms were provided. Abstracts from relevant conferences, pharmaceutical industry submissions to the National Institute for Clinical Excellence (NICE) and the Food and Drug Administration website were also searched. Study selection Study

DARE.2002

128. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

NIHR HTA programme2002

129. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please

NIHR HTA programme2002

130. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35) Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis | Guidance and guidelines | NICE Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis Technology appraisal guidance [TA35] Published date: 27 March 2002 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2002

131. Etanercept

Etanercept Etanercept Etanercept Ansani N Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ansani N. Etanercept. University HealthSystem Consortium (UHC). Drug Monograph. 2000 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug information

Health Technology Assessment (HTA) Database.2000

132. Etanercept (Enbrel(R))

Etanercept (Enbrel(R)) Etanercept (Enbrel(R)) Etanercept (Enbrel(R)) Alberta Heritage Foundation for Medical Research Citation Alberta Heritage Foundation for Medical Research. Etanercept (Enbrel(R)) Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). Emerging Technology Report. 2000 Authors' objectives This report aims to summarise the available evidence on the use of etanercept (Enbrel(R)) in the treatment of rheumatoid arthritis. Authors' conclusions Enbrel(R) has been

Health Technology Assessment (HTA) Database.2000

133. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. 10717011 2000 03 16 2000 03 16 2015 11 19 0028-4793 342 11 2000 Mar 16 The New England journal of medicine N. Engl. J. Med. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. 763-9 We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein (...) , in children with polyarticular juvenile rheumatoid arthritis who did not tolerate or had an inadequate response to methotrexate. Patients 4 to 17 years old received 0.4 mg of etanercept per kilogram of body weight subcutaneously twice weekly for up to three months in the initial, open-label part of a multicenter trial. Those who responded to treatment then entered a double-blind study and were randomly assigned to receive either placebo or etanercept for four months or until a flare of the disease

NEJM2000

134. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. 10972371 2000 09 14 2000 09 14 2015 11 19 0140-6736 356 9227 2000 Jul 29 Lancet (London, England) Lancet Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. 385-90 Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory (...) cytokine, is present in increased concentrations in joints and in the skin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercept. This randomised, double-blind, placebo-controlled, 12 week study assessed the efficacy and safety of etanercept (25 mg twice-weekly subcutaneous injections) or placebo in 60 patients with psoriatic arthritis and psoriasis. Psoriatic arthritis endpoints included the proportion of patients who met the Psoriatic Arthritis Response

Lancet2000

135. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. 11096165 2000 11 14 2000 12 07 2016 11 24 0028-4793 343 22 2000 Nov 30 The New England journal of medicine N. Engl. J. Med. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. 1586-93 Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease activity (...) and preventing joint damage in patients with active early rheumatoid arthritis is unknown. We treated 632 patients with early rheumatoid arthritis with either twice-weekly subcutaneous etanercept (10 or 25 mg) or weekly oral methotrexate (mean, 19 mg per week) for 12 months. Clinical response was defined as the percent improvement in disease activity according to the criteria of the American College of Rheumatology. Bone erosion and joint-space narrowing were measured radiographically and scored with use

NEJM2000

136. Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis

Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis McGahan L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Etanercept: anti-tumor necrosis factor therapy (...) for rheumatoid arthritis. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 1999: 6 Authors' objectives To summarise the available evidence on the use of etanercept, a tumor necrosis factor (TNF) antagonist, in the treatment of rheumatoid arthritis. Authors' conclusions Canadian clinical and economic data comparing methotrexate and etanercept alone versus etanercept in combination with methotrexate would

Health Technology Assessment (HTA) Database.1999

137. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. 9920948 1999 02 02 1999 02 02 2015 11 19 0028-4793 340 4 1999 Jan 28 The New England journal of medicine N. Engl. J. Med. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. 253-9 Patients treated with methotrexate for rheumatoid arthritis often improve (...) but continue to have active disease. This study was undertaken to determine whether the addition of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein (TNFR:Fc), to methotrexate therapy would provide additional benefit to patients who had persistent rheumatoid arthritis despite receiving methotrexate. In a 24-week, double-blind trial, we randomly assigned 89 patients with persistently active rheumatoid arthritis despite at least 6 months of methotrexate therapy at a stable dose

NEJM1999